EUGENIA RESMINI, ANGELO V. CORNAGHI, VALENTINA TURRA, EMANUELA ZARRA, ELENA CIMINO, MARCO SANDRI, MATTEO MIGAZZI, GIULIA MASSARI, BERNADETTA PASQUINO, CRISTINA MASCADRI, SARA MADASCHI, ANGELA GIRELLI
{"title":"935-P: Personality Traits and Glycemic Control in Type 1 Diabetic Patients with Different Insulin Therapies","authors":"EUGENIA RESMINI, ANGELO V. CORNAGHI, VALENTINA TURRA, EMANUELA ZARRA, ELENA CIMINO, MARCO SANDRI, MATTEO MIGAZZI, GIULIA MASSARI, BERNADETTA PASQUINO, CRISTINA MASCADRI, SARA MADASCHI, ANGELA GIRELLI","doi":"10.2337/db25-935-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: Glycemic variability is becoming increasingly important in evaluating effectiveness of treatment in patients with type 1 diabetes. Personality traits may impact daily therapeutic decisions, potentially affecting quality of glycemic control. This study aimed to explore potential relationship between personality traits and glycemic control, and to examine differences across various insulin therapies. Methods: Cross-sectional observational study, 130 type 1 diabetic patients (68 females, 62 males, 43.77±12.81 years, BMI 24.95±4.57 kg/m2, disease duration 23.23±12.39 years, HbA1c 7.04±0.92%), divided in three groups: 1. Multiple daily injections (MDI, n=45); 2. Traditional pumps (TP, n=35); 3. Advanced hybrid closed-loop systems (AHCL, n=50). Personality was assessed through the Personality Inventory for DSM-V questionnaire. Kruskal-Wallis test for independent samples was used to compare continuous variables among three groups. Associations between pairs of variables were analyzed using Spearman’s correlation. Results: AHCL group showed higher emotional lability (p=0.042), perseveration (p=0.005), separation insecurity (p=0.007) and distractibility (p=0.021) than MDI and TP group. The pathological trait of emotional lability (above the 75th percentile) was more frequently present in the AHCL (32%, p=0.029) than MDI and TP group. This trait was associated with an increase in TAR>180 (p=0.035) and GMI (p=0.025), a decrease in TBR<70 (p=0.014). However, glycemic control and metrics were significantly better in the AHCL than MDI and TP group (HbA1c, p=0.03; GRI, p<0.001; TIR, p=0.004; TAR>180, p=0.05; TBR<70, p=0.018, TAR>250, p=0.041; CV, p=0.012; SD, p=0.01). Conclusion: AHCL systems may help mitigating the impact of problematic personality traits, that could interfere achieving an optimal glycemic control. Disclosure E. Resmini: None. A.V. Cornaghi: None. V. Turra: None. E. Zarra: None. E. Cimino: Speaker's Bureau; roche, Abbott. M. Sandri: None. M. Migazzi: None. G. Massari: None. B. Pasquino: None. C. Mascadri: None. S. Madaschi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"10 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-935-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and Objective: Glycemic variability is becoming increasingly important in evaluating effectiveness of treatment in patients with type 1 diabetes. Personality traits may impact daily therapeutic decisions, potentially affecting quality of glycemic control. This study aimed to explore potential relationship between personality traits and glycemic control, and to examine differences across various insulin therapies. Methods: Cross-sectional observational study, 130 type 1 diabetic patients (68 females, 62 males, 43.77±12.81 years, BMI 24.95±4.57 kg/m2, disease duration 23.23±12.39 years, HbA1c 7.04±0.92%), divided in three groups: 1. Multiple daily injections (MDI, n=45); 2. Traditional pumps (TP, n=35); 3. Advanced hybrid closed-loop systems (AHCL, n=50). Personality was assessed through the Personality Inventory for DSM-V questionnaire. Kruskal-Wallis test for independent samples was used to compare continuous variables among three groups. Associations between pairs of variables were analyzed using Spearman’s correlation. Results: AHCL group showed higher emotional lability (p=0.042), perseveration (p=0.005), separation insecurity (p=0.007) and distractibility (p=0.021) than MDI and TP group. The pathological trait of emotional lability (above the 75th percentile) was more frequently present in the AHCL (32%, p=0.029) than MDI and TP group. This trait was associated with an increase in TAR>180 (p=0.035) and GMI (p=0.025), a decrease in TBR<70 (p=0.014). However, glycemic control and metrics were significantly better in the AHCL than MDI and TP group (HbA1c, p=0.03; GRI, p<0.001; TIR, p=0.004; TAR>180, p=0.05; TBR<70, p=0.018, TAR>250, p=0.041; CV, p=0.012; SD, p=0.01). Conclusion: AHCL systems may help mitigating the impact of problematic personality traits, that could interfere achieving an optimal glycemic control. Disclosure E. Resmini: None. A.V. Cornaghi: None. V. Turra: None. E. Zarra: None. E. Cimino: Speaker's Bureau; roche, Abbott. M. Sandri: None. M. Migazzi: None. G. Massari: None. B. Pasquino: None. C. Mascadri: None. S. Madaschi: None. A. Girelli: Consultant; Abbott Diagnostics, Sanofi, Roche Diabetes Care.
期刊介绍:
Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes.
However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.